Jason R. Gotlib

Jason R. Gotlib, associate professor of Medicine (Hematology) at Stanford University Medical Center, discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Gotlib discusses whether next-generation JAK inhibitors should be used after resistance to Jakafi (ruxolitinib) or in the frontline setting. Gotlib also provided an overview of drugs that are being studied in combination with these agents.

 in the category of Commitment to the Individual and is also an international leader in MPN research.

Videos

Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis

Jason R. Gotlib, Associate Professor of Medicine (Hematology) at the Stanford University Medical Center, discusses the research being done at his institution. Gotlib is a 

Recognized for advancing the science of MPNs, Dr. Gotlib is the Principal Investigator for a number of clinical trials in the classic MPNs, and for a database registry specifically for MPN research. In addition, he is acclaimed for his leadership in professional and patient education conferences. Besides mentoring medical fellows and serving as the Editor-in-Chief of 

, Gotlib is highly regarded by his patients for his dedication and sincerity

Jason R. Gotlib discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

Jason R. Gotlib

Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis

Jason R. Gotlib Discusses MPN Research at Stanford

Latest News